NewAmsterdam Pharma Company N.V. (NAMS) Stock Price, News & Analysis

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company focused on research and development in biotechnology. According to its public statements, the company’s mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam is developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), particularly where existing lipid-lowering therapies are not sufficiently effective or are poorly tolerated.

The company’s lead investigational product is obicetrapib, described as a novel, oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor. NewAmsterdam is investigating obicetrapib as a monotherapy and as part of a fixed-dose combination (FDC) with ezetimibe. These LDL-C–lowering therapies are being developed to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. NewAmsterdam characterizes obicetrapib as a next-generation CETP inhibitor intended to address limitations of current LDL-C–lowering treatments.

Clinical development focus

NewAmsterdam describes itself as a late-stage company because obicetrapib has progressed through multiple Phase 2 and Phase 3 clinical trials. Phase 2 trials cited by the company include ROSE2, TULIP, ROSE and OCEAN. Phase 3 trials include BROOKLYN, BROADWAY and TANDEM, which evaluated obicetrapib as monotherapy or in combination therapy. Across these studies, the company reports observing statistically significant LDL-C lowering with a side effect profile similar to placebo.

The company has also initiated and/or is conducting several large Phase 3 programs to further characterize obicetrapib’s effects in high-risk cardiovascular populations:

• PREVAIL Phase 3 cardiovascular outcomes trial (CVOT): Designed to assess whether obicetrapib can reduce major adverse cardiovascular events (MACE) in patients with a history of atherosclerotic cardiovascular disease (ASCVD) whose LDL-C is not adequately controlled despite maximally tolerated lipid-lowering therapy. NewAmsterdam reports that PREVAIL enrolled over 9,500 patients and is intended to evaluate cardiovascular outcomes.
• REMBRANDT Phase 3 imaging trial: A placebo-controlled, double-blind, randomized trial using coronary computed tomography angiography (CCTA) to evaluate the effect of an obicetrapib plus ezetimibe fixed-dose combination on coronary plaque. The trial focuses on adult participants with high-risk ASCVD and evidence of coronary plaque who are not adequately controlled on maximally tolerated lipid-modifying therapy, assessing changes in coronary plaque and inflammation characteristics.
• RUBENS Phase 3 trial: A trial evaluating obicetrapib alone or in combination with ezetimibe in patients with type 2 diabetes and/or metabolic syndrome who require additional LDL-C lowering despite available therapy.

NewAmsterdam has also highlighted a pre-specified Alzheimer’s disease (AD) biomarker analysis within the BROADWAY Phase 3 trial. In this analysis, the company reports statistically significant reductions in plasma p-tau217, a biomarker of AD pathology, in the overall analysis set and in ApoE4 carriers over 12 months, compared with placebo. The company has stated that these findings support an emerging link between CETP inhibition and neurodegeneration and has indicated plans to initiate a dedicated trial of obicetrapib in early Alzheimer’s disease patients.

Therapeutic area and unmet need

NewAmsterdam’s programs are positioned within the broader context of cardiometabolic disease. The company emphasizes that cardiovascular disease remains a leading cause of death globally despite the availability of lipid-lowering therapies. It cites persistent gaps in LDL-C target attainment and residual cardiovascular risk, even among patients treated with high-intensity statins and non-statin lipid-lowering therapies. NewAmsterdam’s stated goal is to address what it describes as a significant unmet need for a safe, well-tolerated and convenient LDL-C–lowering therapy that can be used alongside existing treatments.

In its public materials, the company notes that many adults with elevated LDL-C, including those with ASCVD, do not reach guideline-recommended LDL-C goals. NewAmsterdam frames obicetrapib and its fixed-dose combination with ezetimibe as potential preferred LDL-C–lowering options for patients whose cholesterol levels remain above risk-based targets or who cannot tolerate currently approved therapies.

Regulatory and geographic context

NewAmsterdam Pharma is incorporated in the Netherlands and lists its ordinary shares on the Nasdaq Stock Market under the symbol NAMS. The company has highlighted a partnership with A. Menarini International Licensing S.A. (Menarini), under which commercialization rights for obicetrapib in Europe, either as monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group. Menarini is described as an Italy-based international pharmaceutical and diagnostics company.

NewAmsterdam has announced that marketing authorization applications (MAAs) for obicetrapib 10 mg monotherapy and a 10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination for primary hypercholesterolemia, including heterozygous familial and non-familial or mixed dyslipidemia, were accepted for review by the European Medicines Agency (EMA. The company has also referred to preparations for a potential commercial launch in Europe by Menarini, contingent on a future EMA approval decision.

Research collaborations and scientific dissemination

The company’s development of obicetrapib has been accompanied by scientific publications and conference presentations. NewAmsterdam has reported pooled efficacy and safety data from the pivotal BROADWAY and BROOKLYN Phase 3 trials presented at major cardiology congresses, with simultaneous publication in peer-reviewed journals. It has also highlighted publication of the BROADWAY Alzheimer’s biomarker substudy in The Journal of Prevention of Alzheimer’s Disease, and pooled MACE analyses in the Journal of the American College of Cardiology.

In addition, the REMBRANDT imaging trial is supported by collaboration with Caristo Diagnostics, which serves as the worldwide imaging core lab for coronary plaque and inflammation measurements. According to public information, REMBRANDT uses Caristo’s CaRi-Heart and CaRi-Plaque technologies to quantify noncalcified coronary atherosclerotic plaque volume and coronary inflammation, providing mechanistic insight into obicetrapib’s effects on plaque characteristics.

Capital markets and corporate profile

NewAmsterdam Pharma has communicated its status as a Nasdaq-listed company and has reported using equity-based compensation, including inducement share option grants to non-executive new hires under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The company periodically issues press releases and files current reports on Form 8-K to provide corporate updates, financial results and investor presentations.

Through its focus on CETP inhibition, large cardiovascular outcomes and imaging trials, and exploration of Alzheimer’s disease biomarkers, NewAmsterdam positions itself as a biotechnology company centered on cardiometabolic and related neurodegenerative biology. All of the company’s publicly described clinical-stage efforts are concentrated on obicetrapib and obicetrapib-based combinations, reflecting a targeted development strategy around a single investigational mechanism.